LncRNA RGMB-AS1 Promotes Glioma Growth and Invasion Through miR-1200/HOXB2 Axis

This article was published in the following Dove Press journal:
OncoTargets and Therapy

Bailin Pan¹
Ming Zhao¹
Ning Wang¹
Longbiao Xu¹
Tianya Wu¹
Zequn Li²

¹Department of Neurosurgery, Zhuji People's Hospital of Zhejiang Province, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji 311800, People's Republic of China; ²Department of Neurosurgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People's Republic of China

Background: Dysfunction of long noncoding RNA (lncRNA) is associated with tumorigenesis of various malignancies, including glioma. LncRNA RGMB-AS1 (RGMB antisense RNA 1) has been reported to participate in initiation and progression of several cancers, such as lung cancer, hepatocellular carcinoma and laryngeal squamous cell carcinoma. Nevertheless, whether RGMB-AS1 regulates glioma development is not investigated. In this study, we aimed to determine its roles in glioma.

Methods: qRT-PCR and Western blotting were used to measure gene expression. CCK8 and colony formation assays were utilized to analyze proliferation. Transwell assay was used to determine cell migration and invasion. Luciferase reporter assay was used to validate the interactions among RGMB-AS1, miR-1200 and HOXB2.

Results: RGMB-AS1 was upregulated in glioma tissues and associated with glioma grade and patients' prognosis. Moreover, RGMB-AS1 silencing significantly inhibited the proliferation, migration and invasion of glioma cells. RGMB-AS1 downregulation led to more tumor cells arrested in the quiescent state. Mechanistically, we found that RGMB-AS1 was a molecular sponge for miR-1200. MiR-1200 level was inhibited by RGMB-AS1. And RGMB-AS1 promoted HOXB2 expression via sponging miR-1200. Restoration of HOXB2 effectively rescued the abilities of proliferation, migration and invasion in RGMB-AS1-depleted glioma cells.

Conclusion: Collectively, our work clarified that RGMB-AS1/miR-1200/HOXB2 signaling exerts an essential role in regulating glioma progression.

Keywords: RGMB-AS1, miR-1200, HOXB2, glioma, progression

Introduction

Glioma is one of the most aggressive tumors in the central nervous system (CNS).¹ Until today, it is still difficult to cure glioma and the 5-year survival time of glioma patients is under 15 months.² Although current therapeutic strategies including surgery, radiotherapy and chemotherapy, have achieved advancement, outcomes of glioma patients remain unsatisfactory due to recurrence and metastasis.³ Thus, in-depth understanding the molecular mechanism of glioma development is urgently required.

Long noncoding RNAs (lncRNAs) have no ability to code proteins and are over 200 nucleotides in length.⁴ Numerous references have reported that lncRNAs play vital roles in various biological processes, such as development, immune response and cancer.^{5,6} LncRNA could regulate gene expression at the transcriptional or post-transcriptional level.⁷ Several evidences have indicated that dysregulation of lncRNAs is associated with tumorigenesis.⁸ LncRNA is involved in the regulation of malignant behaviors of cancer cells, such as proliferation and invasiveness.^{9,10} For

Correspondence: Ming Zhao
Department of Neurosurgery, Zhuji People's Hospital of Zhejiang Province, Zhuji Affiliated Hospital of Wenzhou Medical University, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, People's Republic of China
Email ming_zhaomz@sina.com

example, lncRNA POU3F3 promotes growth and invasion of cervical cancer via targeting miR-127-5p/FOXD1 axis.¹¹ LINC01355 inhibited the proliferation and cell-cycle progression in breast cancer via inhibiting CCND1 transcription.¹² Besides, LINC00339 increases proliferation and migration of hepatocellular carcinoma via regulating miR-1182/SKA1 signaling.¹³

RGMB-AS1 was firstly identified as an upregulated lncRNA in non-small cell lung cancer.¹⁴ Subsequently, a study proved that RGMB-AS1 promotes growth and migration of lung cancer cells.¹⁵ Recently, studies also indicate that RGMB-AS1 plays oncogenic roles in hepatocellular carcinoma and laryngeal squamous cell carcinoma.^{16,17} However, its function in glioma remains undetermined. In this study, we found that RGMB-AS1 was upregulated in glioma tissues. Besides, RGMB-AS1 upregulation indicated clinical severity and poor prognosis. Loss-of-RGMB-AS1 induced suppression of proliferation, migration and invasion. In mechanism, we identified that RGMB-AS1 was a sponge for miR-1200 and promotes HOXB2 expression. Taken together, our study reveals that RGMB-AS1 exerts oncogenic roles in glioma through miR-1200/HOXB2 signaling.

Materials and Methods

Clinical Samples

57 glioma tissues and normal controls were collected from Zhuji People's Hospital of Zhejiang Province and stored in the liquid nitrogen. No patient was treated by chemotherapy or radiotherapy before surgery. This study was approved by the Ethics Committee of Zhuji People's Hospital of Zhejiang Province. All experiments using human samples were conducted in accordance with the Declaration of Helsinki. Written informed consent was achieved from each patient.

Cell Culture and Transfection

All glioma cell lines and normal human astrocyte cell line (NHA) were purchased from the Chinese Academy of Sciences cell bank (Shanghai, China). Cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco, NY, USA) supplemented with 10% fetal bovine serum (FBS, ScienCell, LA, USA) and were incubated in an atmosphere containing 5% CO₂ at 37 °C.

qRT-PCR

Total RNA was isolated from tissues or cell lines using TRIzol (Invitrogen, Carlsbad, CA, USA). qPCR was performed using

TaqMan Non-coding RNA Assays and TaqMan miRNA Assays. Relative expression was normalized to GAPDH or U6 and calculated according to the 2^{-ΔΔCt} method. All samples were run in triplicate.

Cell Proliferation Assay

For Cell Counting Kit-8 (CCK8, Dojin, Japan) assay, 2000 cells were seeded in 96-well plates and cultured for indicated times. Then 10 μ CCK8 solution was added and incubated for 2 h. Then the absorbance at 450 nm was measured. For colony formation assay, 500 cells were seeded into 6-well plates and cultured for 14 days. Then colonies were fixed with methanol and stained with 0.1% crystal violet. Colony numbers were then counted.

Cell Migration and Invasion Assays

Transwell assay through a 24-well transwell chamber (8 μm core, Costar, Corning, NY) was performed to determine migration and invasion as described previously.¹⁸

Luciferase Reporter Assay

RGMB-AS1 or HOXB2 3'-UTR sequences containing wide-type (WT) or mutant (MUT) predicted binding site with miR-1200 was inserted into pmirGLO Dual-Luciferase Vector (Promega). For luciferase reporter assay, the luciferase vectors and miR-1200 mimics or negative control (miR-NC) were co-transfected into glioma cells for 48h. Then the relative luciferase activity was determined by using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI) and normalized to Renilla luciferase activity.

RNA Immunoprecipitation

RNA immunoprecipitation (RIP) assay was performed as previously reported.¹⁹

Statistical Analysis

Results were displayed as the mean ± standard deviation (SD) from three independent experiments. Statistical analyses were performed using SPSS 22.0 software by the Student's *t* test, one-way ANOVA or Log rank test. Differences were considered statistically significant when *P* < 0.05.

Results

RGMB-AS1 Was Upregulated in Glioma Tissues

The expression of RGMB-AS1 in glioma tissues was analyzed by qRT-PCR. Results indicated that RGMB-AS1 was

upregulated in glioma tissues (Figure 1A). Furthermore, its level was positively correlated with pathological grades of glioma (Figure 1B). Similarly, RGMB-AS1 expression was elevated in glioma cell lines compared to NHA cells (Figure 1C). In addition, Kaplan-Meier survival analysis implied that RGMB-AS1 high expression predicted low overall survival rate (Figure 1D).

RGMB-AS1 Accelerates Growth, Migration and Invasion of Glioma Cells

To deeply investigate the roles of RGMB-AS1 in glioma, we knocked it down in U87 and LN229 cells (Figure 2A). The effects of RGMB-AS1 on malignant biological behaviors of glioma cells were then examined by CCK8, colony formation, flow cytometry and Transwell assay. RGMB-AS1 knockdown significantly inhibited the proliferation and colony formation compared to si-NC group (Figure 2B and C). Moreover, RGMB-AS1 downregulation increased the cell percent in

G0/G1 phase (Figure 2D and E), suggesting RGMB-AS1 promoted cell-cycle progression. Additionally, reduction of RGMB-AS1 expression impaired the migration and invasion abilities of glioma cells (Figure 2F and G). Similarly, RGMB-AS1 overexpression promoted proliferation, migration and invasion of U87 cells (Figure 2H–J). Thus, above findings suggest that RGMB-AS1 is a novel oncogene in glioma.

Regulatory Relationships Among RGMB-AS1, miR-1200 and HOXB2

LncRNAs have been demonstrated to be miRNA sponges in tumor cells.¹⁷ Thus, we investigated whether RGMB-AS1 could be a molecular sponge for some miRNAs. Using bioinformatics database (miRDB), RGMB-AS1 was identified as a possible sponge for miR-1200 (Figure 3A). To confirm it, we constructed RGMB-AS1 wide-type (WT) and mutant (MUT) luciferase reporter vectors (Figure 3A). Results showed that RGMB-AS1-WT activity was reduced

Figure 1 RGMB-AS1 was upregulated in glioma tissues. (A) Relative expression of RGMB-AS1 in glioma tissues and normal tissues were analyzed by qRT-PCR. (B) Relative expression of RGMB-AS1 in different grades of glioma tissues. (C) Relative expression of RGMB-AS1 in glioma cell lines was determined. (D) Kaplan-Meier overall survival was analyzed according to RGMB-AS1 expression. * $P < 0.05$.

Figure 2 RGMB-AS1 accelerates growth, migration and invasion of glioma cells. (A) RGMB-AS1 expression was determined in U87 and LN229 cells. si-NC: negative control siRNA. (B) CCK8 assay was performed using U87 and LN229 cells transfected with si-RGMB-AS1 or si-NC. (C) RGMB-AS1 knockdown decrease the numbers of colonies. (D and E) Cell-cycle analysis in U87 and LN229 cells after transfection with si-RGMB-AS1 or si-NC. (F and G) Transwell assay showed that RGMB-AS1 knockdown reduced the numbers of migration and invasion. (H) CCK8 assay was performed to analyze proliferation in U87 cells. (I and J) Transwell assay was performed to determine migration and invasion in U87 cells. * $P < 0.05$.

after transfection with miR-1200 mimics (Figure 3B). In addition, RIP assay indicated that RGMB-AS1 and miR-1200 were both enriched by anti-Ago2 in U87 cell lysates (Figure 3C), suggesting RGMB-AS1 and miR-1200 were in an RNA-induced silencing complex (RISC). Of note, RGMB-AS1 knockdown promoted the level of miR-1200 (Figure 3D).

Next, the potential targets of miR-1200 were analyzed using TargetScan7 and miRDB. We identified HOXB2 as the potential target of miR-1200 (Figure 3E). We also constructed HOXB2 WT and MUT luciferase reporter vectors (Figure 3E). Luciferase reporter assay showed that miR-1200

mimics only inhibited the activity of HOXB2-WT reporter (Figure 3F). Moreover, HOXB2 expression was suppressed by miR-1200 mimics (Figure 3G and H). To determine whether HOXB2 expression was regulated by RGMB-AS1/miR-1200 axis, we administrated U87 and LN229 cells with miR-1200 inhibitors and/or RGMB-AS1. As shown, RGMB-AS1 knockdown suppressed HOXB2 expression while si-RGMB-AS1 plus miR-1200 inhibitors rescued HOXB2 expression, and vice versa (Figure 3I and J). Moreover, we found that there was a negative correlation between RGMB-AS1 and miR-1200 or between miR-1200 and HOXB2 in glioma tissues (Figure 3K). Therefore, RGMB-AS1 was

Figure 3 Regulatory relationships among RGMB-AS1, miR-1200 and HOXB2. **(A)** Binding site with miR-1200 in RGMB-AS1 was presented and the response element was mutated. **(B)** Luciferase reporter assay was conducted using RGMB-AS1 wide-type (WT) or mutant (MUT) reporter. **(C)** RIP assay showed that anti-Ago precipitated both RGMB-AS1 and miR-1200 in U87 cell lysates. **(D)** RGMB-AS1 knockdown promoted miR-1200 expression. **(E)** Binding site with miR-1200 in HOXB2 3'-UTR was presented and the response element was mutated. **(F)** Luciferase reporter assay was conducted using HOXB2 3'-UTR wide-type (WT) or mutant (MUT) reporter. **(G and H)** miR-1200 inhibited the mRNA and protein levels of HOXB2. **(I and J)** HOXB2 expression was analyzed after transfection with indicated plasmids. **(K)** Expression correlations among RGMB-AS1, miR-1200 and HOXB2 were analyzed in glioma tissues. * $P < 0.05$.

a molecular sponge for miR-1200 and upregulated HOXB2 expression.

RGMB-AS1 Promoted Glioma Progression Through HOXB2

Interestingly, we found that HOXB2 expression was upregulated in glioma tissues through TCGA database and qRT-PCR results (Figure 4A and B). Moreover, TCGA result indicated that HOXB2 upregulation in glioma patients predicted a low survival rate (Figure 4C), suggesting HOXB2 was an oncogene in glioma and HOXB2 may be a downstream effector of RGMB-AS1/miR-1200 axis. To prove it, we conducted rescue assays. Results showed that HOXB2 restoration rescued the proliferation, migration and invasion of si-RGMB-AS1 transfected glioma cells (Figure 4D–F). Moreover, HOXB2 overexpression accelerated the proliferation, migration and invasion of glioma cells (Figure 4D–F). In conclusion, RGMB-AS1

promoted glioma progression through modulating miR-1200/HOXB2 axis.

Discussion

Increasing numbers of lncRNAs have been demonstrated to be biomarkers or therapeutic targets in glioma. They play vital functions in regulating glioma progression. For example, lncRNA HOTAIRM1 upregulation increases proliferation and metastasis of glioma via promoting HOXA1 expression.²⁰ LncRNA GACAT3 promotes proliferation, migration and invasion of glioma via inhibiting miR-3127.²¹ LncRNA CASC9 promotes glioma cell growth and migration via regulating miR-519d/STAT3 pathway.²² And lncRNA ANRIL modulates growth and cell-cycle of glioma cells through sponging miR-203a.²³ Our present work focused on illustrating the roles of RGMB-AS1 in glioma. Upregulation of RGMB-AS1 has been identified in several cancer types.^{14–17} RGMB-AS1 was upregulated in non-small cell lung cancer.¹⁴ Subsequently, a study proved that RGMB-AS1 promotes

Figure 4 RGMB-AS1 promoted glioma progression through HOXB2. (A) Relative expression of HOXB2 according to TCGA database (<http://gepia.cancer-pku.cn/index.html>). (B) Relative expression of HOXB2 was analyzed by qRT-PCR. (C) Overall survival rate was analyzed according to HOXB2 expression through TCGA database (<http://gepia.cancer-pku.cn/index.html>). (D) CCK8 assay was conducted to analyze proliferation. (E and F) Transwell assay was performed to determine cell migration and invasion. * $P < 0.05$.

growth and migration of lung cancer cells.¹⁵ Recently, studies also indicate that RGMB-AS1 plays oncogenic roles in hepatocellular carcinoma and laryngeal squamous cell carcinoma.^{16,17} However, how it functions in glioma remains undetermined. We found that RGMB-AS1 was upregulated in glioma tissues and cell lines. Moreover RGMB-AS1 upregulation in glioma patients was associated with a low survival rate. Functionally, we showed that RGMB-AS1 downregulation successfully inhibited proliferation, migration and invasion of glioma cells. Our data demonstrated that RGMB-AS1 is a novel oncogene in glioma.

MicroRNAs (miRNAs) are a type of well-known ncRNAs and have less than 22 nucleotides in length. miRNAs are also very important molecules that regulate many biological processes in cancer.²⁴ Large numbers of studies have demonstrated the pivot roles of miRNA in glioma.²⁵ Mechanistically, miRNA could be regulated by lncRNAs, which releases their downstream target.²⁶ In our research, we identified that miR-1200 was sponged by RGMB-AS1 through bioinformatics analysis. We demonstrated the direct interaction between RGMB-AS1 and miR-1200. Moreover, we showed that miR-1200 expression was increased after RGMB-AS1 downregulation in glioma cells. Furthermore, miR-1200 expression was negatively correlated with RGMB-AS1 in glioma tissues. miR-1200 is a poorly studied miRNA. Only one report showed that miR-1200 inhibited osteosarcoma pathogenesis.²⁷ Whether miR-1200 plays a role in glioma is unclear. According to our study, we implied that miR-1200 is a tumor suppressor in glioma for the first time.

The possible downstream target of RGMB-AS1/miR-1200 axis was further identified by bioinformatics analysis. We identified that HOXB2 achieved the highest score. Previous study indicated that miR-1200 targets HOXB2 in osteosarcoma.²⁷ Then through luciferase reporter assay, we demonstrated the direct interaction between miR-1200 and HOXB2 in glioma cells. Moreover, we showed that miR-1200 significantly inhibited the expression of HOXB2 in glioma cells. Interestingly, RGMB-AS1 knockdown suppressed HOXB2 expression in U87 and LN229 cells, which was abrogated by miR-1200 inhibitors. Thus, our findings identified a new signaling cascade of RGMB-AS1/miR-1200/HOXB2 axis. HOXB2 has been reported to participate in progression of several cancers.^{27,28} And a work also indicates that HOXB2 is an oncogene in glioma.²⁹ Consistent with previous study, we also found that HOXB2 was upregulated in glioma tissues. Moreover, we found that HOXB2 is a potential prognostic biomarker. And rescue assay demonstrated that HOXB2 upregulation promoted proliferation,

migration and invasion of glioma cells, further supporting its oncogenic roles in glioma.

In conclusion, our study demonstrated that RGMB-AS1 is a competing endogenous RNA (ceRNA) for miR-1200 to promote HOXB2 expression in glioma. And RGMB-AS1/miR-1200/HOXB2 axis accelerates glioma progression. However, the in vivo assay is required in the future to further confirm the physiological roles of RGMB-AS1/miR-1200/HOXB2 axis.

Acknowledgements

This study was supported by Zhejiang Provincial Natural Science Foundation of China (LY16H090015).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sun G, Zhang C, Song H, Guo J, Li M, Cao Y. WZY-321, a novel evodiamine analog, inhibits glioma cell growth in an autophagy-associated manner. *Oncol Lett.* 2019;17:2465–2472. doi:10.3892/ol.2018.9847
2. Prelaj A, Rebuzzi SE, Grassi M, et al. Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. *Mol Clin Oncol.* 2019;10:58–66. doi:10.3892/mco.2018.1746
3. Liu L, Shi Y, Shi J, et al. The long non-coding RNA SNHG1 promotes glioma progression by competitively binding to miR-194 to regulate PHLDA1 expression. *Cell Death Dis.* 2019;10:463. doi:10.1038/s41419-019-1698-7
4. Chen X, Chen Z, Yu S, et al. Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer. *Clin Cancer Res.* 2018;24:2002–2014. doi:10.1158/1078-0432.CCR-17-2376
5. Liu B, Ye B, Yang L, et al. Long noncoding RNA lncKdm2b is required for ILC3 maintenance by initiation of Zfp292 expression. *Nat Immunol.* 2017;18:499–508. doi:10.1038/ni.3712
6. Wang KC, Chang HY. Molecular mechanisms of long noncoding RNAs. *Mol Cell.* 2011;43:904–914. doi:10.1016/j.molcel.2011.08.018
7. Zhang Y, Yang G, Luo Y. Long non-coding RNA PVT1 promotes glioma cell proliferation and invasion by targeting miR-200a. *Exp Ther Med.* 2019;17:1337–1345. doi:10.3892/etm.2018.7083
8. Sun S, Gong C, Yuan K. LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/beta-catenin signaling pathway. *Exp Ther Med.* 2019;17:1182–1189. doi:10.3892/etm.2018.7097
9. Yue C, Ren Y, Ge H, et al. Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. *Onco Targets Ther.* 2019;12:561–576. doi:10.2147/OTT.S188913
10. Guo LP, Zhang ZJ, Li RT, Li HY, Cui YQ. Influences of LncRNA SNHG20 on proliferation and apoptosis of glioma cells through regulating the PTEN/PI3K/AKT signaling pathway. *Eur Rev Med Pharmacol Sci.* 2019;23:253–261. doi:10.26355/eurrev_201901_16771
11. Chang S, Sun L, Feng G. SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXO1. *Biomed Pharmacother.* 2019;117:109133. doi:10.1016/j.biopha.2019.109133

12. Ai B, Kong X, Wang X, et al. LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1. *Cell Death Dis.* **2019**;10:502. doi:10.1038/s41419-019-1741-8
13. Xiao J, Yu H, Ma Z. LINC00339 promotes growth and invasiveness of hepatocellular carcinoma by the miR-1182/SKA1 pathway. *Oncotargets Ther.* **2019**;12:4481–4488. doi:10.2147/OTT.S207397
14. Li P, Li J, Yang R, et al. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer. *Diagn Pathol.* **2015**;10:63. doi:10.1186/s13000-015-0297-x
15. Li P, Zhang G, Li J, et al. Long noncoding RNA RGMB-AS1 indicates a poor prognosis and modulates cell proliferation, migration and invasion in lung adenocarcinoma. *PLoS One.* **2016**;11:e0150790.
16. Sheng N, Li Y, Qian R, Li Y. The clinical significance and biological function of lncRNA RGMB-AS1 in hepatocellular carcinoma. *Biomed Pharmacother.* **2018**;98:577–584. doi:10.1016/j.biopha.2017.12.067
17. Xu Z, Xi K. LncRNA RGMB-AS1 promotes laryngeal squamous cell carcinoma cells progression via sponging miR-22/NLRP3 axis. *Biomed Pharmacother.* **2019**;118:109222. doi:10.1016/j.biopha.2019.109222
18. Feng L, He M, Rao M, Diao J, Zhu Y. Long noncoding RNA DLEU1 aggravates glioma progression via the miR-421/MEF2D axis. *Oncotargets Ther.* **2019**;12:5405–5414. doi:10.2147/OTT.S207542
19. Chen Y, Bao C, Zhang X, Lin X, Huang H, Wang Z. Long non-coding RNA HCG11 modulates glioma progression through cooperating with miR-496/CPEB3 axis. *Cell Prolif.* **2019**;52(5): e12615.
20. Li Q, Dong C, Cui J, Wang Y, Hong X. Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme. *J Exp Clin Cancer Res.* **2018**;37:265. doi:10.1186/s13046-018-0941-x
21. Pan BL, Zhao M, Xu LB. Long noncoding RNA gastric cancer-associated transcript 3 plays oncogenic roles in glioma through sponging miR-3127-5p. *J Cell Physiol.* **2019**;234:8825–8833. doi:10.1002/jcp.v234.6
22. Liu HJ, Li C, Yang JK, et al. Long noncoding RNA CASC9/miR-519d/STAT3 positive feedback loop facilitate the glioma tumorigenesis. *J Cell Mol Med.* **2018**;22:6338–6344. doi:10.1111/jcmm.2018.22.issue-12
23. Dai W, Tian C, Jin S. Effect of lncRNA ANRIL silencing on anoikis and cell cycle in human glioma via microRNA-203a. *Oncotargets Ther.* **2018**;11:5103–5109. doi:10.2147/OTT.S169809
24. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. *Carcinogenesis.* **2007**;28:2–12. doi:10.1093/carcin/bgl1185
25. He X, Fan S. hsa-miR-212 modulates the radiosensitivity of glioma cells by targeting BRCA1. *Oncol Rep.* **2018**;39:977–984. doi:10.3892/or.2017.6156
26. Lian Y, Xiong F, Yang LT, et al. Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. *J Exp Clin Cancer Res.* **2018**;37. doi:10.1186/s13046-018-0918-9
27. Li SL, Pei Y, Wang W, Liu F, Zheng K, Zhang XJ. Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2. *Cell Cycle.* **2019**;18(11):1281–1291.
28. Lindblad O, Chougule RA, Moharram SA, et al. The role of HOXB2 and HOXB3 in acute myeloid leukemia. *Biochem Biophys Res Commun.* **2015**;467:742–747. doi:10.1016/j.bbrc.2015.10.071
29. Chen X, Li LQ, Qiu X, Wu H. Long non-coding RNA HOXB-AS1 promotes proliferation, migration and invasion of glioblastoma cells via HOXB-AS1/miR-885-3p/HOXB2 axis. *Neoplasma.* **2019**;66(3):386–396. doi:10.4149/neo_2018_180606N377

OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

Dovepress